• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Big Cypress Acquisition Corp.

    10/22/21 4:18:33 PM ET
    $BCYP
    Finance
    Get the next $BCYP alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-39871
    Issuer: Big Cypress Acquisition Corp.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 300 W. 41st Street
    Suite 202
    Miami Beach FLORIDA 33140
    Telephone number: (305) 204-3338
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    units
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2021-10-22 By Tara Petta AVP
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BCYP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCYP

    DatePrice TargetRatingAnalyst
    10/4/2021$18.00Outperform
    Northland Capital Markets
    10/1/2021$16.50Buy
    Ladenburg Thalmann
    More analyst ratings

    $BCYP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company

      Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol "SABS" SIOUX FALLS, S.D., Oct. 25, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the completion of its business combination with Big Cypress Acquisition Corp. (NASDAQ:BCYP) ("Big Cypress"), a publicly-traded special purpose acquisition company (SPAC) focused on innovative biopharmaceutical

      10/25/21 7:39:57 AM ET
      $BCYP
      Finance
    • Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics

      MIAMI, Oct. 21, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ:BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that its stockholders have approved the proposed business combination (the "Business Combination") with SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs in infectious disease and immune system disorders, at a Special Meeting of stockholders held on October 20, 2021 (the "Special Meeting"). Approximately 98.3% of t

      10/21/21 7:00:00 AM ET
      $BCYP
      Finance
    • SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021

      SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that it will host a virtual R&D Day on Wednesday, October 13, 2021, at 10:00 a.m. ET to showcase its versatile DiversitAb™ platform and pipeline of clinical and preclinical programs. The event will feature SAB management and key opinion leaders, including: Arturo Casadevall, MD, PhD – The Alfred and Jill Sommer Professor and Chair, W. Harry Feinstone Department of Molecular Microbiology & Immunology, Bloomberg Distinguished Professor, Johns Hopkins B

      10/6/21 7:00:00 AM ET
      $BCYP
      Finance

    $BCYP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Carillo Carlos N

      4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

      10/26/21 9:53:55 PM ET
      $BCYP
      Finance
    • SEC Form 4 filed by Erickson Bruce Kipp

      4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

      10/26/21 9:53:05 PM ET
      $BCYP
      Finance
    • SEC Form 4 filed by Wu Hua

      4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

      10/26/21 9:52:27 PM ET
      $BCYP
      Finance

    $BCYP
    SEC Filings

    See more
    • Big Cypress Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Change in Shell Company Status

      8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)

      10/28/21 5:16:44 PM ET
      $BCYP
      Finance
    • SEC Form 25-NSE filed by Big Cypress Acquisition Corp.

      25-NSE - Big Cypress Acquisition Corp. (0001833214) (Subject)

      10/22/21 4:18:33 PM ET
      $BCYP
      Finance
    • Big Cypress Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Big Cypress Acquisition Corp. (0001833214) (Filer)

      10/21/21 7:30:47 AM ET
      $BCYP
      Finance

    $BCYP
    Leadership Updates

    Live Leadership Updates

    See more
    • SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

      SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appointment of Russell Beyer as chief financial officer (CFO), effective September 20, 2021. Mr. Beyer will lead all aspects of SAB's financial operations and key supporting functions and will work with the senior management team to drive SAB's growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005435/en/(Photo: Business Wire) "We welcome Russell to the SAB team at an exciting t

      9/28/21 7:00:00 AM ET
      $BCYP
      Finance

    $BCYP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Big Cypress Acquisition Corp.

      SC 13D - SAB Biotherapeutics, Inc. (0001833214) (Subject)

      11/1/21 7:38:40 PM ET
      $BCYP
      Finance
    • SEC Form SC 13D filed by Big Cypress Acquisition Corp.

      SC 13D - SAB Biotherapeutics, Inc. (0001833214) (Subject)

      11/1/21 4:57:43 PM ET
      $BCYP
      Finance
    • SEC Form SC 13D filed by Big Cypress Acquisition Corp.

      SC 13D - SAB Biotherapeutics, Inc. (0001833214) (Subject)

      11/1/21 4:55:01 PM ET
      $BCYP
      Finance

    $BCYP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Northland Capital Markets initiated coverage on Big Cypress Acquisition with a new price target

      Northland Capital Markets initiated coverage of Big Cypress Acquisition with a rating of Outperform and set a new price target of $18.00

      10/4/21 10:23:14 AM ET
      $BCYP
      Finance
    • Ladenburg Thalmann initiated coverage on Big Cypress Acquisition with a new price target

      Ladenburg Thalmann initiated coverage of Big Cypress Acquisition with a rating of Buy and set a new price target of $16.50

      10/1/21 7:00:04 AM ET
      $BCYP
      Finance